ASIM Joins Coalition in Effort to Bring Tobacco Industry Under FDA Control
WASHINGTON--The American Society of Internal Medicine (ASIM) joined the Coalition on Smoking OR Health in its effort to create FDA oversight of the tobacco industry. ASIM's policy on tobacco supports stronger cigarette labels,
WASHINGTON--The American Society of Internal Medicine (ASIM) joinedthe Coalition on Smoking OR Health in its effort to create FDAoversight of the tobacco industry. ASIM's policy on tobacco supportsstronger cigarette labels, increasing the legal age to buy tobaccoproducts to 21, and a ban on tobacco advertising or at least eliminationof its tax deductibility.
Articles in this issue
Selecting a Support Group for Patients With Prostate Carcinoma
Antman Provides Outlook on Use of High-Dose Chemo
Radiofrequency Ablation of Brain Tumors New Option
Oncologist Enthusiastic About Capitated Plan
Digital Mammography Has Potential to Detect Small Tumors, Increase Accuracy in Dense Breasts
GAO Says Federal Research Needed on Safety of Portable Cellular Telephones
Varmins Chooses New Director for NIH Office of Alternative Medicine
Identifying the 'Sentinel' Lymph Node May Obviate Need for Total Axillary Dissection
'Visible Man' Hits the Internet, Radiologists Get the First Look
Ultrafast Full-Body MRI Eases Procedure in Claustrophobics, Kids
WHO Melanoma Study: Interferon Boosts Disease-Free Survival
Coram to Purchase Caremark's Home Infusion Therapy Business
NCCR Unveils Six New Public Service TV Announcements
GAO Says Federal Research Needed on Safety of Portable Cellular Telephones
Breast Examination Center of Harlem Expands Service
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
